The addition of Brandwood CKC is aimed to provide PharmaLex with greater visibility in Australia and New Zealand
PharmaLex Group has completed the merger of Brandwood CKC to the PharmaLex Group
With more than 20 years of experience, Brandwood CKC offers regulatory, technical and commercial services for medical devices and medicinal products in Australia, New Zealand and the broader APAC region. Based in Sydney, NSW, the company has international presence in Los Angeles, Wellington, Taipei and Hong Kong. The companies say they share “the same value proposition, mindset and culture.”
“Becoming part of the PharmaLex Group is an exciting step for Brandwood CKC”, said Grant Bennett, CEO, Brandwood CKC. “It allows us to expand the range of services we can provide to our clients as well as supporting PharmaLex by providing specific expertise in areas such as medical devices”, he added.
“The merger aligns with our objective to strengthen our presence in Australia, New Zealand and the broader global markets of Asia-Pacific region”, said Dr Thomas Dobmeyer, CEO PharmaLex. “Brandwood CKC has a strong client base and coupled with the additional services we offer, we hope this will enable us to gain greater visibility and support our international clients to get their products successfully approved and marketed in this important .”